Skip to main content
Erschienen in: Journal of Nuclear Cardiology 3/2020

01.11.2018 | Original Article

Prognostic values of 123I-MIBG myocardial scintigraphy and heart rate variability in patients with heart failure with preserved ejection fraction

verfasst von: Hidenobu Hashimoto, MD, PhD, Rine Nakanishi, MD, PhD, Sunao Mizumura, MD, PhD, Yukiko Hashimoto, MD, PhD, Yuriko Okamura, MD, Kyoko Yamanaka, MD, Junichi Yamazaki, MD, PhD, Takanori Ikeda, MD, PhD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to evaluate the prognostic values of sympathetic nerve system using 123I-MIBG myocardial scintigraphy and using Holter electrocardiogram (ECG) in patients with heart failure with preserved ejection fraction (HFpEF).

Methods and results

Among 403 consecutive patients with stable HF who underwent 123I-MIBG myocardial scintigraphy and Holter ECG, we identified 133 patients (64 ± 16 years) who had preserved ejection fraction (≥ 50%) by echocardiography. Multivariate Cox model was used to assess if washout rate (WR) by 123I-MIBG scintigraphy and very low frequency power (VLFP) by Holter ECG was associated with major adverse cardiovascular events (MACE). During a mean follow-up of 5.4 ± 4.1 years, 39 MACE occurred. The lower nighttime VLFP (HR 3.29, 95% CI 1.56 to 6.92) and higher WR (HR 4.01, 95% CI 1.63 to 9.88) were the significant prognostic factors for MACE. As compared to high nighttime VLFP and low WR group, MACE risk was significantly the highest in the low nighttime VLFP and high WR group (HR 40.832; 95% CI 5.378 to 310.012, P < 0.001).

Conclusion

This study demonstrated that the nighttime VLFP adding to WR could be a potential prognostic value among patients with HFpEF.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Levy WC, Anand IS. Heart failure risk prediction models: What have we learned? JACC Heart Fail. 2014;2:437–9.CrossRef Levy WC, Anand IS. Heart failure risk prediction models: What have we learned? JACC Heart Fail. 2014;2:437–9.CrossRef
2.
Zurück zum Zitat Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.CrossRef Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.CrossRef
3.
Zurück zum Zitat Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.CrossRef Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.CrossRef
4.
Zurück zum Zitat Packer M. The neurohumoral hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–54.CrossRef Packer M. The neurohumoral hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–54.CrossRef
5.
Zurück zum Zitat Agostini D, Carrio I, Verberne HJ. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging. 2009;36:555–9.CrossRef Agostini D, Carrio I, Verberne HJ. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging. 2009;36:555–9.CrossRef
6.
Zurück zum Zitat Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, et al. Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun. 2005;26:97–102.CrossRef Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, et al. Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun. 2005;26:97–102.CrossRef
7.
Zurück zum Zitat Katoh S, Shishido T, Kutsuzawa D, Arimoto T, Netsu S, Funayama A, et al. Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med. 2010;24:679–86.CrossRef Katoh S, Shishido T, Kutsuzawa D, Arimoto T, Netsu S, Funayama A, et al. Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med. 2010;24:679–86.CrossRef
8.
Zurück zum Zitat Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standard of measurement, physiological interpretation, and clinical use. Circulation. 1996;93:1043–65.CrossRef Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standard of measurement, physiological interpretation, and clinical use. Circulation. 1996;93:1043–65.CrossRef
9.
Zurück zum Zitat Bonaduce D, Petretta M, Marciano F, Vicario ML, Apicella C, Rao MA, et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. Am Heart J. 1999;138:273–84.CrossRef Bonaduce D, Petretta M, Marciano F, Vicario ML, Apicella C, Rao MA, et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. Am Heart J. 1999;138:273–84.CrossRef
10.
Zurück zum Zitat Kurata C, Shouda S, Mikami T, Uehara A, Ishikawa K, Tawarahara K, et al. Metaiodobenzylguanidine and heart rate variability in heart failure. Jpn Circ J. 1998;62:770–2.CrossRef Kurata C, Shouda S, Mikami T, Uehara A, Ishikawa K, Tawarahara K, et al. Metaiodobenzylguanidine and heart rate variability in heart failure. Jpn Circ J. 1998;62:770–2.CrossRef
11.
Zurück zum Zitat Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Emande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.CrossRef Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Emande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.CrossRef
12.
Zurück zum Zitat Jessup M, Marwick TH, Ponikowski P, Voors AA, Yancy CW. 2016 ESC and ACC/AHA/HFSA heart failure guideline update—What is new and why is it important? Nat Rev Cardiol. 2016;13:623–8.CrossRef Jessup M, Marwick TH, Ponikowski P, Voors AA, Yancy CW. 2016 ESC and ACC/AHA/HFSA heart failure guideline update—What is new and why is it important? Nat Rev Cardiol. 2016;13:623–8.CrossRef
13.
Zurück zum Zitat Ohtomo N, Terachi S, Tanaka Y, Tokiwano K, Kaneko N. New method of time series analysis and its application to Wolf’s sunspot number data. Jpn J Appl Phys. 1994;33:2821–31.CrossRef Ohtomo N, Terachi S, Tanaka Y, Tokiwano K, Kaneko N. New method of time series analysis and its application to Wolf’s sunspot number data. Jpn J Appl Phys. 1994;33:2821–31.CrossRef
14.
Zurück zum Zitat Donal E, Lund LH, Oqer E, Hage C, Persson H, Reynaud A, et al. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: A subanalysis of the Ka (Karolinska) Ren (Rennes) Study. Eur J Heart Fail. 2015;17:680–8.CrossRef Donal E, Lund LH, Oqer E, Hage C, Persson H, Reynaud A, et al. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: A subanalysis of the Ka (Karolinska) Ren (Rennes) Study. Eur J Heart Fail. 2015;17:680–8.CrossRef
15.
Zurück zum Zitat Kizman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–50.CrossRef Kizman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–50.CrossRef
16.
Zurück zum Zitat Levi R, Silver RB, Mackins CJ, Seyedi N, Koyama M. Activation of a renin-angiotensin system in ischemic cardiac sympathetic nerve endings and its association with norepinephrine release. Int Immunopharmacol. 2002;2:1965–73.CrossRef Levi R, Silver RB, Mackins CJ, Seyedi N, Koyama M. Activation of a renin-angiotensin system in ischemic cardiac sympathetic nerve endings and its association with norepinephrine release. Int Immunopharmacol. 2002;2:1965–73.CrossRef
17.
Zurück zum Zitat Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231–8.CrossRef Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231–8.CrossRef
18.
Zurück zum Zitat Bigger JT, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart rate variability and mortality after myocardial infarction. Circulation. 1992;85:164–71.CrossRef Bigger JT, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart rate variability and mortality after myocardial infarction. Circulation. 1992;85:164–71.CrossRef
19.
Zurück zum Zitat Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation. 1991;84:482–92.CrossRef Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation. 1991;84:482–92.CrossRef
20.
Zurück zum Zitat Parti G, Saul JP, Di Rieuzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation: A critical appraisal. Hypertension. 1995;25:1276–86.CrossRef Parti G, Saul JP, Di Rieuzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation: A critical appraisal. Hypertension. 1995;25:1276–86.CrossRef
21.
Zurück zum Zitat Morata A, Sleight P, Pinna GD, Maestri R, Prpa A, La Rovere MT, et al. Abnormal awake respiratory patters are common in chronic heart failure and may prevent evaluation of autonomic tone by measures of heart rate variability. Circulation. 1997;96:246–52.CrossRef Morata A, Sleight P, Pinna GD, Maestri R, Prpa A, La Rovere MT, et al. Abnormal awake respiratory patters are common in chronic heart failure and may prevent evaluation of autonomic tone by measures of heart rate variability. Circulation. 1997;96:246–52.CrossRef
22.
Zurück zum Zitat Ushijima R, Joho S, Akabane T, Oda Y, Inoue H. Differing effects of adaptive servoventilation and continuous positive airway pressure on muscle sympathetic nerve activity in patients with heart failure. Circ J. 2014;78:1387–95.CrossRef Ushijima R, Joho S, Akabane T, Oda Y, Inoue H. Differing effects of adaptive servoventilation and continuous positive airway pressure on muscle sympathetic nerve activity in patients with heart failure. Circ J. 2014;78:1387–95.CrossRef
23.
Zurück zum Zitat Kario K. Morning surge and variability in blood pressure: a new therapeutic target? Hypertension. 2005;45:485–6.CrossRef Kario K. Morning surge and variability in blood pressure: a new therapeutic target? Hypertension. 2005;45:485–6.CrossRef
Metadaten
Titel
Prognostic values of 123I-MIBG myocardial scintigraphy and heart rate variability in patients with heart failure with preserved ejection fraction
verfasst von
Hidenobu Hashimoto, MD, PhD
Rine Nakanishi, MD, PhD
Sunao Mizumura, MD, PhD
Yukiko Hashimoto, MD, PhD
Yuriko Okamura, MD
Kyoko Yamanaka, MD
Junichi Yamazaki, MD, PhD
Takanori Ikeda, MD, PhD
Publikationsdatum
01.11.2018
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 3/2020
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-018-01494-x

Weitere Artikel der Ausgabe 3/2020

Journal of Nuclear Cardiology 3/2020 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.